This study checks if a medicine called **VGA039** can help people with a bleeding problem called **Von Willebrand Disease (VWD)**. The medicine is given under the skin, called **subcutaneous (SC) injection**. This study is in **Phase 3**, which means it's close to being available for everyone if it works well and is safe.
In the study, there's an **Observational Period** for at least **24 weeks** where doctors watch patients closely. Then, for about **49 weeks**, patients get the VGA039 medicine. They will write down any bleeding they have and how they treat it in a diary. Doctors will check for any side effects during the whole study.
**Key Points:** - **Duration:** The study lasts over a year, including both observation and treatment periods. - **Participation Requirements:** Participants should be aged 12 to 75 and have a VWD diagnosis. - **Exclusions:** People who already use certain bleeding preventions or have other health issues may not join.Participants help find out if VGA039 works and is safe, but they should be ready for regular check-ups and diary entries.